Status:

ENROLLING_BY_INVITATION

Effectiveness and Safety of Outpatient Treatment of Uncomplicated Acute Diverticulitis Without Antibiotics

Lead Sponsor:

Monica Mengual Ballester

Conditions:

Diverticulitis, Colonic

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

The objective of this clinical trial to evaluate the effectiveness and safety of outpatient treatment without antibiotics compared to outpatient treatment with antibiotics in patients with acute uncom...

Detailed Description

The surgeon must reassess the patient at 72 hours, with a complete history of the new clinical status, physical examination, and blood tests (with the same parameters). This visit will check treatment...

Eligibility Criteria

Inclusion

  • Patients over 18 years old with clinical and radiological diagnosis of acute sigmoid or descending colon diverticulitis (left-sided acute diverticulitis) not complicated.
  • Radiological diagnosis of acute uncomplicated diverticulitis by CT (Modified Hinchey Classification 0-Ia).
  • First episode or previous history of acute diverticulitis (both complicated and uncomplicated), with ≥6 months between the last episode and the current clinical presentation).
  • Informed consent to participate in the study.

Exclusion

  • Age \>80 years.
  • Patients eligible for hospital admission and/or intravenous antibiotic therapy (at the time of diagnosis).
  • Repeated vomiting or oral intolerance.
  • Need for intravenous fluid therapy and/or close monitoring.
  • Peripheral body temperature \>38ºC.
  • Deterioration of general condition and/or clinical suspicion of sepsis.
  • Significant or decompensated comorbidity: ASA IV Classification (anesthetic risk of American Society of Anesthesiologists).
  • Immunocompromised patients: Hematological cause, HIV with low CD4+ levels, immunosuppressive treatment, prolonged corticosteroid therapy, chemotherapy, transplanted or splenectomized patients, predisposing genetic alterations (severe combined immunodeficiency, etc.).
  • Oral or intravenous antibiotic therapy 2 weeks before the onset of symptoms for another cause.
  • Pregnancy.
  • Inflammatory bowel disease (Crohn's disease, ulcerative colitis).
  • Lack of social and home support making outpatient treatment and follow-up impossible.

Key Trial Info

Start Date :

November 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 30 2026

Estimated Enrollment :

282 Patients enrolled

Trial Details

Trial ID

NCT06517264

Start Date

November 1 2024

End Date

April 30 2026

Last Update

February 25 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Monica Mengual

Murcia, Spain, 30007